Key Takeaways Same ingredient, different approvals – Both Zepbound and Mounjaro contain tirzepatide, but Zepbound is FDA-approved for chronic weight management, while Mounjaro is approved for type 2 diabetes. Weight loss outcomes – Clinical trials show Zepbound users achieve greater average weight loss (up to ~22%) compared with Mounjaro users (~15%), reflecting its weight-focused dosing protocols. Coverage drives access – Insurance typically favors Mounjaro for diabetes,

August 18, 2025, Novo Nordisk has reduced the out-of-pocket cost of Ozempic® (semaglutide) to $499 per month for U.S. patients with type...